Linagliptin & Metformin Hydrochloride ER Tablets – LAGLIN-M 5/500 Tablets

LAGLIN-M 5/500 Tablets – Achieving Effective Glycemic Control with Linagliptin & Dapagliflozin.

LAGLIN-M 5/500 Tablets – The Dual Combination of Linagliptin 5 mg + Metformin 500mg (ER) Tablets are specifically formulated to manage Type-2 Diabetes Mellitus (T2DM). The combination contains Dapagliflozin (an SGLT-2 inhibitor) and Linagliptin (a DPP-4 inhibitor) which helps effectively control blood sugar levels in individuals with type 2 diabetes.

Key Benefits of Linagliptin & Metformin Hydrochloride ER Tablets – LAGLIN-M 5/500 Tablets
✅Dual Action for Comprehensive Glycemic Control: Linagliptin boosts insulin secretion and reduces glucose production in the liver, while Dapagliflozin promotes glucose excretion via the kidneys. This combined approach provides a thorough solution for controlling blood sugar in type 2 diabetes.
✅Low Risk of Hypoglycemia: The combination generally carries a low risk of hypoglycemia (low blood sugar), offering a safer, more comfortable option compared to other glucose-lowering treatments that may lead to hypoglycemia.
✅Convenient Once-Daily Dosing: With once-daily dosing, this combination makes it easier for patients to stay on track with their treatment, improving overall adherence and long-term compliance.

Recommended By Specialists:
👨‍⚕️Diabetologists: Specialized in diabetes care, to improve glycemic control, especially in patients with poor response to single drug therapy.
👨‍⚕️Endocrinologists: Primary prescribers for type 2 diabetes which is often recommended when monotherapy (either metformin or a DPP-4 inhibitor like linagliptin) is insufficient to control blood glucose levels.
👨‍⚕️General Physicians: For managing type 2 diabetes in patients who need oral combination therapy to effectively control blood sugar.

INDICATIONS:
✅Type 2 Diabetes Mellitus
✅Fasting and Postprandial Hyperglycemia
✅Overweight or High-Risk Patients